Abstract
Objectives: We performed a prospective randomized and controlled animal study to investigate the effects of infliximab on experimental otitis media in rats. Methods: Seventy-two Sprague-Dawley rats were randomly allocated to 3 study groups and 1 control group. Infliximab was injected intravenously. Histopathologic changes were determined by hematoxylin-eosin staining. Fluorescence microscopy was performed to examine the leakage of the exudates. Vascular permeability was measured by the Evans blue dye technique. Results: In comparison with the control group, we found significant differences in the extent of middle ear mucosa without active inflammation and the presence of reparable lesions in all study groups treated with infliximab. A significant reduction of extravasated Evans blue dye in all study group animals was found as compared with the control group animals. Conclusions: This study suggests that the monoclonal tumor necrosis factor α antibody, infliximab, can reduce inflammatory activity in experimental otitis media in rats.
| Original language | English |
|---|---|
| Pages (from-to) | 470-476 |
| Number of pages | 7 |
| Journal | Annals of Otology, Rhinology and Laryngology |
| Volume | 117 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2008 |
Bibliographical note
Funding Information:From the Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. This study was supported by the otolaryngology alumni, The Catholic University of Korea, and by the clinical research laboratory, Uijeongbu St Mary's Hospital. This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act (7 U.S.C. et seq).
Keywords
- Anti-inflammatory agent
- Infliximab
- Monoclonal antibody
- Otitis media
- Rat
- Tumor necrosis factor α